早期乳腺癌辅助化疗与靶向治疗选择:ASCO临床实践指南重点更新
ASCO专家组基于靶向系统性文献综述,更新早期乳腺癌辅助化疗和靶向治疗推荐;推荐HER2阴性且有残留侵袭性疾病者可辅助卡培他滨最多6-8周期,高风险HER2阳性者可加用1年帕妥珠单抗,可延长奈拉替尼辅助治疗但需预防腹泻。
要点
- HER2阴性术前化疗后残留侵袭性疾病可辅助卡培他滨最多6-8周期。
- 高风险早期HER2阳性可加用1年帕妥珠单抗联合曲妥珠方案。
- 早期HER2阳性可延长奈拉替尼辅助治疗,但必须预防腹泻。
核心结论
- HER2阴性术前化疗后残留侵袭性疾病可辅助卡培他滨最多6-8周期。
- 高风险早期HER2阳性可加用1年帕妥珠单抗联合曲妥珠方案。
- 早期HER2阳性可延长奈拉替尼辅助治疗,但必须预防腹泻。
研究设计与样本
- ASCO专家组采用信号方法进行靶向系统性文献综述。
- 综述评估了辅助卡培他滨、帕妥珠单抗和奈拉替尼的III期试验。
主要发现
- 专家组审查了HER2阴性术后残留侵袭性疾病辅助卡培他滨的III期试验。
- 专家组审查了早期HER2阳性辅助帕妥珠单抗1年联合化疗和曲妥珠单抗的III期试验。
- 专家组审查了早期HER2阳性曲妥珠单抗辅助治疗后延长奈拉替尼辅助治疗的III期试验。
关键数值与推荐
- HER2阴性早期乳腺癌术前蒽环和紫杉类化疗后手术有病理侵袭性残留者,可辅助卡培他滨最多6-8周期。
- 高风险早期HER2阳性乳腺癌,临床医生可在曲妥珠单抗联合化疗基础上加用1年帕妥珠单抗。
- 早期HER2阳性乳腺癌,临床医生可在曲妥珠单抗后使用奈拉替尼延长辅助治疗。
- 奈拉替尼引起明显腹泻,必须使用腹泻预防措施。
临床怎么用
- HER2阴性术前化疗后残留侵袭性疾病者可考虑辅助卡培他滨最多6-8周期。
- 高风险早期HER2阳性可考虑加用1年帕妥珠单抗联合曲妥珠方案。
- 早期HER2阳性可考虑奈拉替尼延长辅助治疗,但必须预防腹泻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer. Methods An Expert Panel conducted targeted systematic literature reviews guided by a signals approach to identify new, potentially practice-changing data that might translate to revised practice recommendations. Results The Expert Panel reviewed phase III trials that evaluated adjuvant capecitabine after completion of standard preoperative anthracycline- and taxane-based combination chemotherapy by patients with early-stage breast cancer HER2-negative breast cancer with residual invasive disease at surgery; the addition of 1 year of adjuvant pertuzumab to combination chemotherapy and trastuzumab for patients with early-stage, HER2-positive breast cancer; and the use of neratinib as extended adjuvant therapy for patients after combination chemotherapy and trastuzumab-based adjuvant therapy with early-stage, HER2-positive breast cancer. Recommendations Patients with early-stage HER2-negative breast cancer with pathologic, invasive residual disease at surgery following standard anthracycline- and taxane-based preoperative therapy may be offered up to six to eight cycles of adjuvant capecitabine. Clinicians may add 1 year of adjuvant pertuzumab to trastuzumab-based combination chemotherapy in patients with high-risk, early-stage, HER2-positive breast cancer. Clinicians may use extended adjuvant therapy with neratinib to follow trastuzumab in patients with early-stage, HER2-positive breast cancer. Neratinib causes substantial diarrhea, and diarrhea prophylaxis must be used. Additional information can be found at www.asco.org/breast-cancer-guidelines .
引用
- Denduluri N, Chavez-MacGregor M, Telli ML, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018. PMID: 29787356. doi:10.1200/JCO.2018.78.8604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。